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All herpesviruses are capable ofremaining latent in host cells subsequent to pri-
mary infection. Understandingthe mechanism bywhich these virusesestablish and
maintain latency and undergo reactivation is critical to understanding the biology
and clinical consequences of herpesvirus infection. EBV is a lymphotropic herpes-
virus that infects the majority ofthe human population subclinically. The virus is
the causative agent ofinfectious mononucleosis and is associated with nasopharyn-
geal carcinoma and the endemic form ofBurkitt's lymphoma (BL)1 (1, 2). In addi-
tion, EBVcontaining B cell lymphomas are known to occur in immunosuppressed
persons, such as organ transplant recipients treated with cyclosporin A, and indi-
viduals with AIDS (3, 4). EBV can also infect human peripheral blood B cells in
vitro, and this system currently provides the most accessible model for the study
of herpesvirus latency.
In vitro latent infection with EBV causes B cells tobecome activated. It has been
shown that EBVinfected cells express the B cell activation antigen CD23 (Blast-2)
and show increased RNA content and synthesis by 24 h. The expression ofCD23
is predictiveofsubsequent proliferation that occurs at 2-3 d post-infection (5). Un-
like other agents of B cell activation, EBV does not induce the cells to terminally
differentiate; rather, the infected cells maintain a blastoid state and proliferate per-
manently. The derivation oflymphoblastoid cell lines that arelatently infectedwith
EBV is, therefore, a two-step process involving activation and immortalization.
The latently infected B cells also express characteristic viral markers. These in-
clude the Epstein Barr nuclear antigens (EBNAs) (6-10), and the latent membrane
protein, which is capable of transforming established rodent cell lines (11).
The onset oflatency is also accompanied by structural changes within the viral
genome. EBV is a dsDNA virus of ti170 kb, the genome ofwhich is linear in the
virion (12). In latently infected cells, however, the viral DNA is present as a cova-
lently closed, circular episome (CCC) (13, 14). The termini of the linear EBV ge-
nome are composed ofavariable number of directly repeated sequences. The pro-
cess ofcircularization most likely involves recombination between repeat units on
theopposing termini, and the numberofterminalrepeats(TR) usedtoform a CCC
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is characteristic of any circularization event (15, 16). Latently infected cells contain
multiple copies of the circular viral genome due to amplification of viral relative
to cellular DNA (17). The production of a circular EBV genome is a crucial step
in the immortalization process as it establishes the genome in the state in which
it can persist in the infected B cell and thus ensures continued cellular proliferation.
In this paper we have examined the circularization event in newly infected B cells
in vitro in relation to the processes of B cell activation and immortalization.
Materials and Methods
CellLines.
￿
The BL cell lines Raji and Ramos were obtained from American Type Culture
Collection (Rockville, MD), and BL2 was a kind gift ofDr. G. Lenoir (IARC, Lyon, France).
These lines were maintained in RPMI 1640 supplemented with 10% FCS and antibiotics
at 370C and split to 0.3 x 106/ml twice weekly. The EBVproducing marmoset cell line B958
was a kind gift ofDr. E. Kieff(Harvard University Medical School, Boston, MA) and main-
tained as above, except that it was fed with 8% FCS. The P3HRI cell line, a kind gift of
Dr. M. Nonoyama (Showa University Research Institute, St. Petersburg, FL), was main-
tained in RPMI 1640 with 5° FCS and antibiotics at 34°C.
Virus.
￿
B958 or P3HRI cell lines were seeded at 0.3-0.4 x 106/ml. Supernatant fluids
from these cultures were harvested 7 d later by centrifugation at 2,000 rpm for 15 min at
4°C. Aliquots were frozen at -70°C and used as a source of infectious virus. The TD50
of B95-8 stocks was estimated to be 5 x 105/ml.
Purification ofB Cells.
￿
Whole peripheral blood cells, obtained by venipuncture ofhealthy
donors, or by-products ofplatelet pheresis, obtained from the Blood Bank ofthe Dana Farber
Cancer Institute (Boston, MA), were centrifuged over Ficoll-Hypaque to obtain PBL. En-
richment for B cells was accomplished by either oftwo methods. In some instances, the B cells
were purified by positive selection on columns ofSephadex-coupled rabbit anti-human Fab
and eluted with 1 % human gamma globulin, as described previously (18). An alternative
method used was negative selection of B cells by incubation ofPBL with SRBCs treated with
Neuraminidase (Gibco Laboratories, Grand Island, NY). PBL were incubated with SRBCs
at 4'C for 1 h, centrifuged over Ficoll-Hypaque, and the nonrosetting fraction, containing
B cells and macrophages, was subjected to adherence on plastic or glass at 37°C for 1 h or
more. Nonadherent cells were then decanted and used as a source of B cells. A second roset-
ting did not appreciably enrich for B cells. Both of these methods yielded <1% T cells and
<10% macrophages, as determined by indirect immunofluorescence using mAbs specific for
T cell (OKT3) or macrophage (M02) markers. Greater than 90% of these cells reacted with
antibody to the B cell-specific marker Bl.
Infections.
￿
For infections using undiluted viral supernatant (all infections unless other-
wise noted), 4 x 106 purified B cells were suspended in 1 ml viral supernatant and incubated
at 37°C. At 2 h post-infection, an equal volume of RPMI 1640 containing 207o FCS and
antibiotics was added. Cells were fed approximately every 3 d by diluting the culture with
RPMI 1640/20% FCS.
Gardella Gel Technique.
￿
Analysis of viral DNA was carried out by the method ofGardella
et al. (19), with modifications. This technique allows the resolution oflinear and circular viral
DNA from EBVinfected cells. Horizontal gels of0.75 % agarose were poured. The area above
the wells was removed and replaced with 0.8% agarose containing 20 7o SDS and 1 mg/ml
pronase. 106 or 2.5 x 106 whole cells were placed in each well. Electrophoresis was carried
out at 4°C at 30 V for 2-3 h, at which time the voltage was increased to 160 V for an addi-
tional 14-18 h. Gels were then stained with ethidium bromide (0.5 wg/ml) for 0.5-1 h, depu-
rinated with HCI, denatured with NaOH,and neutralized as described. Transfer was accom-
plished by the method of Southern (20) onto ~ probe membranes (Bio-Rad Laboratories,
Richmond, CA). Blots were baked for 1-2 h at 80°C in a vacuum oven. Hybridization to
nick-translated fragments ofthe EBV genome was performed according to standard methods
(21). In many of these experiments, the Bam HI W fragment of the genome was used as
a probe. However, if blots were erased and reprobed with the Bam HI L, Bam HI K, orHURLEY AND THORLEYLAWSON
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Mlu subfragment of the Barn Nhet (see below) fragment of the genome, the signals obtained
were similar in relative intensity. In their initial report, Gardella et al. (19) could detect as
few as 0.25 EBV genome equivalents using this technique. By optimizing conditions, we have
detected as few as 0.05 genome equivalents per cell.
Quantitation of EBV Genomes within Infected Cells.
￿
The number of circular and linear viral
genomms within EBVinfected cells was estimated by comparison to serial dilutions of the
Raji BL cell line. Raji cells, which contain _60 (published estimates give an average of 56
t 8) EBV genome copies per cell (22), were serially diluted with EBV- BL cells, either
Ramos or BL2. The diluted Raji cells were subjected to electrophoresis on Gardella gels,
blotted, and hybridized in parallel with equal numbers ofthe experimental cells (for example,
see Fig. 2). The signals obtained upon autoradiography were scanned with a scanning den-
sitometer (LKB Instruments, Inc., Gaithersburg, MD). The area under each curve obtained
by densitometry was plotted against genome number (typically, from 60 down to 1/16 of a
genome equivalent) and used to generate a standard curve. Experimental values were then
determined by measuring the area under the curve obtained by densitometry of the ex-
perimental samples and calculating a genome number per cell from the Raji cell standard
curve. A similar method has been used to estimate EBV genome numbers in infected cells
by whole cell DNA dot blot (23). In various established cell lines, the estimated genome numbers
we obtain using this system are concordant with published values to _20-30%.
Inhibitors.
￿
For mitomycin C treatment, B cells were purified from peripheral blood, washed,
and resuspended at 107 cells/ml in RPMI 1640 containing 50 ug mitomycin C (Sigma Chem-
ical Co., St. Louis, MO). This concentration is sufficient to completely inhibit proliferation
of mitogen-treated B cells. The cells were incubated at 37°C for 0.5 h, washed four times,
and resuspended at 4 x 106/ml in B958 viral supernatant. Control cells were treated in the
same manner, except mitomycin C was excluded. Cells were harvested on days 1, 2, and 3
post-infection.
For experiments with other inhibitors, cells were treated with 100 AM Acyclovir (ACV;
Burroughs Wellcome Co., Greenville, NC) (90% inhibition of viral capsid antigen produc-
tion in P3HR1), 1 or 10 wg/ml actinomycin D (Sigma Chemical Co.) (>99% inhibition of
[3H]thymidine incorporation at both concentrations), 5, 20, or 50 Pg/ml cycloheximide
(Sigma Chemical Co.) (98% inhibition of [3H]leucine incorporation at all three concentra-
tions), or 20 or 50 Ag/ml Arabinoside C (Ara C; Upjohn Co., Kalamazoo, MI) (92% .and
96% inhibition of [3H]thymidine incorporation, respectively), for 1 h before infection, and
the drugs were maintained in the culture throughout the course of the infection. Cells were
harvested at 2-3 d post-infection. Ficoll-Hypaque density centrifugation was performed be-
fore harvesting, and cells were >90% viable as judged by trypan blue exclusion.
Isolation ofNuclei.
￿
Nuclei were extracted from cells at 48 h post-infection using 0.5% NP-
40, as described by Benz and Strominger (24). Upon Wright-Giemsa staining, <10% of the
nuclei showed associated cytoplasmic staining.
EBNA Staining .
￿
EBNA staining was carried out by anti-complement immunofluorescence
as describedby Reedman and Klein (25). Positive serum was obtained from a donor seroposi-
tive for EBV, and complement and negative serum were obtained from an EBV seronegative
donor.
Cytofluorographic Analysis.
￿
For analysis, _106 cells were washed in RPMI 1640 containing
1% FCS. The cells were then resuspended in 100 IL1 of hybridoma ascites of various anti-
bodies and isotype-matched negative controls, diluted 1:100. For cell sorting, 107 cells per
tube (total of 108) were washed and resuspended in 200 Al EBVCS hybridoma ascites; EBVCS
recognizes the CD23 (Blast-2) B cell activation antigen, and was a kind gift ofDr. B. Sugden
(University ofWisconsin, Madison, WI). Cells were incubated with the antibodies for 20 min
at 4°C, washed twice, and resuspended in 100 Al (for analysis) or 200 Al (for sorting) FITC-
labeled goat anti-mouse Ig (Cappel Laboratories, Cochranville, PA), diluted 1 :20. Cells were
incubated another 20 min at 4°C, washed twice, and resuspended at 106/ml (for analysis)
or 8 x 106/ml (for sorting). Analysis was performed on a FAGS IV. Sorting was carried out
on an EPICS cell sorter. For sorting experiments, only small lymphocytes were collected to
avoid contamination by lymphoblasts or monocytes. The 20% most and least fluorescent
cells were collected as CD23' and CD23- populations, respectively.2062
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Cloning.
￿
Cells were cloned on day 6 post-infection by limiting dilution. Microtiter plates
containing 1, 10, and 100 cells per well were established on a feeder layer ofirradiated human
foreskin fibroblasts (350 Q. Wells were fed approximatelyonce every week by removing half
the volume and replacing it with fresh medium (RPMI, 20% FCS, antibiotics). Clonality
of the cell lines was determined by analysis of Ig gene rearrangements on Southern blots.
Analysis ofEBRterminal Fragments in Clonal Cell Lines.
￿
High molecular weight DNA from
EBVinfected B cell clones or lineswas extracted essentially as described (21). 1-10 jig ofpurified
cellular DNA was digested with 10-20 U of Barn H1, subjected to electrophoresis on 0.6%
agarose gels, and Southern blotted onto ~ probe membranes. Blots were then hybridized to
an Mlu subfragment ofthe Barn Hl Nhet fragment ofEBV, which corresponds to the right-
hand end ofthe genome (11). The Mlu fragment was obtained by Bam Hl digestion ofplasmid
pHS1-LM, a kind gift of Dr. E. Kieff (Harvard University Medical School, Boston, MA).
This fragment was labeled with '2P by the random priming method according to the
manufacturer's specifications (Boehringer Mannheim Biochemicals, Indianapolis, IN). Upon
circularization of the linear viral genome, Barn Nhet is linked to sequences in the left-hand
end of the genome (Bam Jhet), to form CCC containing a new restriction fragment, Bam
NJhet. When CCC are digested with Barn HI, Southern blotted, and hybridized to the Mlu
probe, the size ofBarn NJhet varies from 8 to 11.5 kb, depending on the number ofTR used
to form the CCC. Bam NJhet contains 7.5 kb unique DNA and its total molecular weight
varies in increments of 500 bp, the size of the repeat unit (26).
Results
Circular ViralGenomes Can beDetected within EBV-infected Celtsby .20 hAfterInfection.
￿
The
EBV genome in the virion is linear; however, in stably transformed LCL, the latent
genome persists as multiple covaientlyclosed circles. To determine when the transi-
tion from the linear to the circular form occurs, peripheral blood B cells were in-
fected with the B95-8 strain of EBV and harvested at various times after infection.
Linear and circular viral genomes were then separated using the Gardella gel tech-
nique and detected by Southern blotting and hybridization to EBVspecific probes.
As shown in Fig. 1, CCC were apparent by 20 h post-infection; however, in some
experiments they were detected as early as 16 h post-infection. Only a small amount
of the total EBV DNA within the infected cells assumed a circular configuration;
the majority of the viral DNA retained the linear form.
Distribution ofEBVGenomes within Infected Cellsfrom O to 48h Post-infection.
￿
To ana-
lyze the fate of EBV DNA in a quantitative fashion, we measured the amount of
linear and circular DNA present at various times after infection. A summary of the
results is presented in Table 1. In this experiment, the highest multiplicity ofvirus
obtainable was used in order to illustrate the relevant events most clearly; however,
the distribution ofviral genomes within newly infected cellswas always similar, regard-
less of the multiplicity used. When we analyzed an aliquot of our virus preparation,
we found that under the experimental conditions used, B cells were exposed to -170
linear genomes per cell. By 6 h post-infection, an average of 30-40 linear genomes
were associated with each cell, of which, seven remained cell associated by 48 h.
At this time approximately one-fourth of the linear genomes were found in the nu-
clear fraction. Analysis of CCC at 48 h revealed an average of 0.16 per cell. There-
fore, we may conclude that at most 16% of the cells exposed to EBV contained a
viral genome in its latent form, and that only 0.1% of the original input genomes
and 5% of the cell-associated genomes became CCC .
Production ofa Circular EBV Genome Can Be Correlated with a Specific Stage in B Cell
Activation.
￿
The first detection of CCC at 16-20 h post-infection suggests that cir-cularïzation of EBV genomms occurs sometime before the activated B cells begin
proliferating. To better define the level ofcellular activation required forthe genome
to circularize, we blocked the infection process at various stages .
To determine ifcellularDNAsynthesis wasnecessary for theproduction ofCCC,
cells were treated with the DNA synthesis inhibitor mitomycinC and then exten-
sively washed to remove excess drug before infection . These cells showed no reduc-
tion in circular viral genome number at 2 d post-infection (Fig . 2 A) despite their
HURLEY AND THORLEYLAWSON
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TABLE I
Fate of Infectious Virus from 0 to 48 h Post-infection
FIGURE 1 .
￿
Kinetics of appearance ofCCC
withinnewlyEBVinfectedBcells. Bcellswere
harvested at 2, 4, 6, 20, and 48 h post-
infection, analyzed by Gardella gels, Southern
blotted, and hybridized to an EBVspecific
probe.
Linear viral
￿
Circular viral
genomes per cell
￿
genomes per cell
Cells were harvested at 0, 6, and 48 h post-infection, analyzed on Gardella gels,
Southern blotted, and hybridized to EBV-specific probes . Numbers ofviral ge-
nomes were estimated by scanning densitometry and comparison to populations
ofRaji cells that were subjected to the same procedure . See Fig. 2A for represen-
tative Raji cell serial dilution with EBV - BL cells .
2063
0 Input genomes 170 <0.10
6 Whole cell 30-40 <0.10
48 Whole cell 6.7 0.16
48 Nuclei 1 .8 0.162064
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inability to proliferate. Entry of infected cells into S phase is, therefore, not a pre-
requisite for the production of CCC.
Inhibitors of the viraland cellular DNA polymerases were also examined for their
ability to inhibit production of circular EBV genomes. In these experiments, cells
were treated with the inhibitors before and during the infection process and exam-
ined forthe presence of circular genomesat days 2-3 post-infection. When cellswere
treated with the viral DNA polymerase inhibitor, ACV, there was no effect on the
number of CCC detected (Fig. 2B), indicating that theviralpolymerase is notneces-
sary for production ofCCC. Cells were also exposed to the DNA polymerase inhib-
itor Ara C, which inhibits cellular as well as viral DNA polymerase activities. This
treatment resulted in abolishment of detectable circularization (Fig. 2 B). Since cel-
lular DNA synthesis per se is not required for circularization, it therefore appears
that cellular DNA polymerase may be required for the transition of the virus from
the linear to the circular form.
As mentioned above, infected cells do not need to enter S phase in order for cir-
cularization of the EBV genome to occur. To determine if progression through the
G1 phase of the cell cycle is necessary, cells were infected with the P3HRI strain
ofEBV. P3HRI is anontransformingstrain of EBV that lacks the gene forthe latent
viral nuclear protein EBNA2, and P3HRI-infected B cells show no reactivity with
anti-EBNA sera (27, 28). Infection with P3HRI induces B cells to progress through
Go and enter the early G1 phase (GIA) of the cell cycle but not late G1 (GIB) or S
phases (29). As shown in Fig. 2 C, P3HRI-infected B cells contained CCC at 2-3
d post-infection. Therefore, neither entry of infected cells into GIB nor expression
of the EBNA gene products are necessary for the production of CCC.
To assess whether RNA or protein synthesis were required for circularization to
occur, cells were treated with the RNA synthesis inhibitor, actinomycin D, or the
protein synthesis inhibitor, cycloheximide. Infected cellsmaintained on theseagents
do not express the B cell activation antigen CD23 (Blast-2) or enter Gi (5). At 2-3
d post-infection, cells treated with these inhibitors do not contain CCC (Fig. 2 B).
This result indicates that the de novo protein and RNA synthesis required for CD23
expression and entry into G1 are also required for the production of CCC. There-
fore, it appears that B cells must be activated to late Go (GoB) or GIA, but not GIB
in order for circularization to occur.
The Presence of Circular Viral Genomes Correlates with Expression of the B Cell Activation
Antigen CD23 (Blast-2). Given that circularization occurs at an earlystage ofB cell
activation, we reasoned that the presence of CCC should correlatewith the expres-
sion ofearlysurfacemarkers ofinfection or activation. It has been shown previously
that more cells express EBNA upon infection than actually become immortalized.
Only those EBNA+ cells that simultaneously express the B cell activation antigen
CD23 proceed to immortalize (5). In any givenexperiment, we foundthat thenumber
of CCC correlated closely with the number of cells expressing CD23, rather than
the number expressing EBNA. This correlation suggested the possibility that the
same cells express CD23 andcontain asingle CCC. If this were true, then thepres-
ence of CCC would be predictive of immortalization. To test whether this was the
case, B cells were separated by FRCS into CD23+ and CD23- populations at 36
h post-infection and analyzed for the presence of CCC. Although the CD23+ cells
were activated, they should not have become proliferating blasts until 48-72 h post-2066
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infection . However, to avoid contamination by B cells that were already activated
at the time of infection, blastoid cells were excluded by selecting for small cells be-
fore CD23 selection . When the unselected andCD23+ populations were analyzed
for CCC, it was found that there were 1.3 CCC/CD23+ cell in the unselected popu-
lation, and 1.0 CCC/CD23+ cell in the selected population (Fig. 3, Table II) . As
these two numbers are not significantly different, this result suggests that there is
direct concordance between CD23 expression and the presence of a single CCC.
This conclusion was further corroborated by the observation that noCCC were de-
tected (<0.10 per cell) in the CD23 - population . Thus, only CD23+ cells that con-
tain CCC at 36 h post-infection proceed to immortalize .
Amplification of Circular Viral DNA Is not Essential for the Establishment of Latency.
Amplification ofCCC relative to cellularDNA has been demonstrated in cell lines
latently infected with EBV (17) . To examine the kinetics of amplification of the one
CCC present in CD23+ cells at 36 h, we performed extended time course analyses
from days 2-12 post-infection . Results of a typical experiment, in which two dilu-
tions of viral supernatant were used, are shown in Fig. 4. The number ofCCC de-
tected early after infection was proportional to the amount of input virus (Fig . 4
and data not shown), indicating that this, rather than the fraction ofinfectable cells,
was limiting on the number of CCC detected . Cultures exposed to undiluted viral
supernatant contained essentially 100% EBNA+ cells by day 8 (data not shown),
indicating that they were all infected . In addition, all cells expressed CD23 (Fig.
5), indicating that they were immortalized B lymphoblasts . At this time, there was
an average of one CCC per cell, with only residual linear viral DNA remaining.
Since all of these cells were infected and immortalized, each must contain a viral
genome, as opposed to a few cellscontaining multiple viralgenomes and others con-
taining none . Amplification of the viral genome in the cells infected with undiluted
FIGURE 3 .
￿
Analysis of viral DNA within CD23' and CD23 -
populations . Infected cells were separated by FACS at 36 h into
CD23+ and CD23- populations . These were then analyzed by
the Gardella gel technique along with unselected cellsHURLEY AND THORLEYLAWSON
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TABLE II
Quantitation of Circular Viral DNA within CD23* and CD23 - Cells
The numberof circular viral genomes per cell was determined by scanning den-
sitometry of the bands shown in Fig . 3, and comparison to a Raji cell standard
curve . The percentage of CD23 * cells was obtained by post-sorting analysis of
the individual fractions .
viral supernatant was not detected until day 10, when two CCC per cell were de-
tected . Interestingly, we observed that the initiation of amplification could consis-
tently be correlated with the loss of incoming linear viral DNA (Fig . 4 and data
not shown) . Thefact that amplification did not occur until 1 wk after all ofthemarkers
characteristic of latent infection had appeared indicates that amplification of cir-
cularviralDNA is not necessary forB cell activation or the establishment of latent
infection by EBV .
FIGURE 4.
￿
Analysis of linear
and circular viral DNA from
days 2-12 post-infection . Cells
infected with undiluted or a
half-diluted preparation ofviral
supernatant were harvested on
days 2, 4, 6, 8, 10, and 12 (un-
diluted only) post-infection and
analyzed for the presence of cir-
cular and linear viral DNA .
Numbers of circular genomes
per cell are indicated at thebot-
tom of the figure .
CD23 selection
Circular
genomes per cell
Percent
CD23 * cells
Circular genomes
per CD23 * cell
None (unseparated) 0.5 40 1 .3
Negative <0 .13 <0 .1 -
Positive 0 .8 83 0.962068
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FIGURE 5.
￿
CD23 expression on day 8 post-infection .
The infected cell population was stained for CD23 ex-
pression by indirect immunofluorescence using the
EBVCS2 antibody on day 8 post-infection. Heavy line,
anti-CD23; lightline, control isotype-matched antibody.
Clonal Cell Lines Contain a Clonal Population of EBVEpisomes.
￿
Our analysis sug-
geststhat a single viral genome circularizes in an infected cell and subsequently pro-
ceeds to amplify, giving rise to multiple episomes. If this hypothesis is correct, then
clonal cell lines derived from infections, such as those shown in Fig. 4, should con-
tain aclonal population of viral episomes. When a CCC is formed, varyingnumbers
of the 500-bp direct terminal repeat may be used. If multiple circularization events
occur in a single cell, the resulting clonal cell line will contain multiple fused ter-
minal fragments, whereas, if a single event occurs, only one predominant fragment
will be detected. Therefore, Southern blots of Bam HI-digested DNA from five in-
dependent clonal cell lines were hybridized to a probe corresponding to unique DNA
contained within the right-most Bam H1 fragment of the EBV genome in order to
determine the number of fused terminal fragments each clone contained. Newly
established polyclonal cell lines contained eight different EBVterminal fragments
(Fig. 6), varying in size from 8 to 11 .5 kb, in increments of 500 bp. In contrast, the
cloned cell linesshowed either asingle sized fragment hybridizingto the probe (clones
C2, E5, and H8), or one major hybridizing species, with several minor bands (D9,
F8) (Fig. 6). The latter pattern has been observed previously in clonal cell lines that
were originally infected with a single genome (16) . Furthermore, the size of the
hybridizingfragment within each clone wasdistinct from that within anyother clone.
This finding indicates that these five clones arose independently. The independent
andclonal nature ofthese lineswas also confirmedby analysis ofIg gene rearrange-
ments within the cells (data not shown). Therefore, our results demonstrate that
the multiple CCC genomes in our clones arose from a single genome that circular-
ized and subsequently amplified.
CCCReplicate butDo notAmplify Early after Infection.
￿
As mentioned above, before
the initiation of amplification, CCC were maintained at one per CD23+ cell. We
wished to determine whether or not the viral genome was able to replicate during
this time. Therefore, we performed aquantitative analysis oftotal CCC and linear
viral genomes in a given culture over time. From days 1 to 11 post-infection, the
number of CCC increased exponentially over time (Fig. 7) in parallel with cellular
proliferation (data not shown). In contrast, input linear viral DNA was gradually
lost, and by day 7 only a constant residual amount of linear viral DNA remainedHURLEY AND THORLEYLAWSON
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FIGURE 6 .
￿
Analysis of EBV
fused termini in polyclonal and
monoclonal cell lines . High mo-
lecular weight DNA was ex-
tracted from the B958 cell line,
polyclonal cell lines at day 20
or 29 post-infection, and five
EBVinfected B cell clones (C2,
D9, E5, F8, H8). The DNA
was digested with Barn Hl, sub-
jected to electrophoresis, and
Southern blotted and hybrid-
ized to a probe specific for
unique DNA contained within
the right-most Bam Hl frag-
ment of the EBV genome .
in the population . This amount would not be sufficient to account for the increase
in CCC occurring at this time. Therefore, we may conclude that the resident CCC
genome replicates as the cell divides, and by extrapolation, commences replication
at the onset of cellular proliferation . By extrapolation of the graphs shown in Fig .
7 back to time zero, we also find that 1 of every 1,000 input genomesbecome aCCC.
This result is consistent with the data shown in Table I .
Discussion
The present study was undertaken to identify cellular events critical to the estab-
lishment oflatency in EBVinfected B cells. Ourfindings indicate that when B cells
were exposed to multiple linear viral genomes only a small fraction reached the nu-2070
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cleus and became circular. The B cells must be activated in order forthis to occur;
however, the cells do not need to progress further than early G, (GIA). This is con-
sistent with the first detection o£ CCC at 16-20 h post-infection.
We have also observed a concordance between the presence o£CCC and the ex-
pression ofthe B cell activation marker CD23. CD23 is one ofthe earliest markers
to appear on activatedB cells and isexpressed at anelevatedlevelon EBVtransformed
B cells (5). It has been reported that membrane triggering through virion binding
cienttoinduce CD23(29). This occurs within 6h ofinfection, even withinac-
defective viruses. This level ofCD23 expression is low, and we have not
detected it in our experiments. We do not find CD23 expression until 24 h post-
infection. Inourexperiments thelevel ofexpression ofCD23 ishigh, similarto that
oftransformed B cells, and is only detected on 15-20% ofthe infected cells. Al-
though thispopulation consists ofsmallrestingcells,the presence ofCD23is predictive
that they will subsequently blast transform and proliferate (5). Our current study
suggests that this subpopulationofcellsalsocontain asingle CCC. Therelationship
betweenCD23 expression andthe presence ofCCC is mostlikely explained by our
observation that a certain level of cellular activation is required before CCC can
form. However, this level is not characterized by elevated CD23 expression since
P3HR-1-infected cells can form CCC but do not express elevated CD23, and cir-
FIGURE 7.
￿
Quantitation oflinear and
circular viral genomes in theinfected
cell population from days 2-11 post-
infection. An arbitrarynumberofcells
wasanalyzed viatheGardella geltech
linear and
ular viral DNA were quantitated
ning densitometry. The num-
bers obtained by densitometry were
multiplied by thetotalnumber ofcells
in theculture on the day of the anal-
ysisto givethetotalnumber ofcircular
or linearviralgenomesin the infected
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cularization (16-20 h) occurs before elevated CD23 (ti24 h). Activation is probably
required to produce cellularproteins necessary forcircularization, such as the DNA
polymerase. Thus, elevated CD23 expression presumably only occurs in the popu-
lation of infected B cells thut .already contain a CCC. One explanation for this de-
pendence would be that the CCC form is required for the appropriate viral tran-
scription to cause subsequent elevated CD23 expression. Thus, it has been suggested
that one viral gene, EBNA-2, directly upregulates CD23, based on the infection or
transfection of EBV- Burkitt's lymphoma lines (30, 31). However, we favor the no-
tion that EBV latent gene products do not cause atypically high levels of CD23 ex-
pression but rather fix the activated Bcells at a very specific stageof B cell differenti-
ation that in normal B cells is characterized by elevated CD23 expression and
proliferation. In this context it is noteworthy that CD23 itself has been directly im-
plicated in the autocrine growth of both normal and EBVtransformed B lympho-
cytes (32). This idea predicts that other EBVlatent gene products couldhave asimilar
effect to EBNA-2 and is supported by the observation that EBV+ lymphomas tend
to change in culture to a lymphoblastoid phenotype, includingelevated CD23 (33).
A candidate for the normal cellular counterpart of the EBVactivated B cell could
be B cells activated by IL-4 plus anti-IgM, which have recently been demonstrated
to express equivalent levels of CD23 (34).
Previous studies indicated that the inhibition of the EBV transforming function
by y or X irradiation follows one-hit kinetics, leading the authors to suggest that
circularizationof theviral genome maybe necessary for theestablishment oflatency
(35, 36). This observation is consistent with oursuggestion that CCC appear before
and are required for CD23 expression and subsequent proliferation. Circulariza-
tion may be essentialforseveral reasons. First, replication of thelatent genome pre-
sumably requires the CCC form, and failure to replicate will eventually lead to loss
of the viral genome and cell death. In addition, circularization could repress genes
associated with the lytic cycle, in addition to being required for the expression of
latent genes. For example, upon circularization, sequences at the termini, which
are separated by >170 kb in the linear form, are brought in close proximity to one
another. Indeed, the transcription unit of a recently described EBVlatent gene spans
theTR, necessitating circularization foritsexpression (37). Furthermore, theCCC
form of the viral genome may be required for the correct transcription of the large
transcriptional unit that encodes the EBNA proteins (38).
We have also noted that CCC occur preferentially in the B cells that are in the
high density fraction at infection (datanot shown). Thesecells also have more linear
genomes associated with them earlyafterinfection, suggesting that they simply have
an increased probability of receiving an intact genome that can form a CCC and
drive the cell on to CD23 expression. This also explains the observation that the
CD23 + population at 36 h is enriched for the presence of linear genomes.
For a CCC to form, the viral DNA must be internalized and reach the nucleus
of the infected cell. We have found that only 51 7b of the genomes that become cell
associated actually reach the nucleus, indicating that entry into the nucleus is lim-
iting in determining the number of viral genomes that become CCC. In addition,
linear viral DNA reaching the nucleus must be full length, containing at least one
repeat unit at each end, in order for circularization to occur. It has been suggested
that only 12.5% of EBV genomes of the B95-8 strain are sufficiently intact to cir-2072
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cularize in vitro (15). Our results are consistent with this hypothesis, since 9% of
the genomes that reach the nucleus become CCC, suggesting that thereis a random
probability that any viral genome reaches the nucleus, and that the integrity of the
viral DNA reaching the nucleus is limiting in the production of CCC. As the cells
begin to proliferate, linear viral genomes are gradually lost, while CCC are main-
tained at one copy per cell dueto replication, rather than segregation of input linear
viralgenomesto daughter cells and furthercircularization. By day7-10 post-infection,
when only latently infected EBNA and CD23+ cells remained in culture, each cell
still contained only one CCC. The conclusion that there was a single viral genome
was based on quantitative estimation; however, it was independently confirmed by
demonstrating that clonal cell lines derived in our experiments contained a clonal
population of viral episomes.
Amplification of the viral genome has been shown to occur in cells latently in-
fected with EBV (17). In contrast to the initial circularization of a linear genome,
which determines whichcells will immortalize, establishment ofthe circularized ge-
nome at a high copy number is not necessary for the establishment of latency.
Amplification was not detected in our experiments until well after the cells had ac-
quired all of the markers characteristic of latent infection, and had been prolifer-
ating for >1 wk. Interestingly, the initiation of amplification appears to require a
low genome copy number within the infected cell. Over a range of multiplicities
of infection, amplificationwasnot seen until all incoming linear DNA waslost (Fig.
4 and data not shown). It is possible that linear and circular viral genomes com-
pete for limiting amounts of viral or cellular factors necessary for amplification.
Amplification might commence only when the genome copy number if sufficiently
low, and cease when the numbers of CCC are high enough that the levels of these
factorsare againlimiting. Alternatively, trans-acting repressors ofamplification, perhaps
linked to the lytic cycle, could be expressed by linear viral genomes, but not CCC.
We have concluded that, in our experiments, a single viral genome circularizes
andis responsible for immortalizinga single cell. That single genome then amplifies,
generating the multiple CCC seen in established lines. There are, however, other
interpretations of our observations. For example, it could be argued that an unde-
tectable fraction of cells circularize multiple incoming genomes and that only these
cells immortalize, giving rise to high copy number cell lines. We have eliminated
this possibility by showingthat regardless ofthegenome copy number within acloned
line, each contained only one predominant fused terminal fragment. Thus, each
clone initially contained a single circular genome that subsequently amplified to give
rise to many genome copies.
Anotherpossibility is that theCCC in a minority ofcells undergoesamplification
very early after infection, and only these cells are capable of immortalizing. In this
case, we would expect that apopulation ofnewly infected cells, in whichonly a small
fraction ofcellshave amplifiedviralDNA, would have amuch lower cloningefficiency
than an established cell line, in which most or all of the cells would have amplified
viral DNA. However, these two populations of cells clone with the same efficiency,
indicating that amplification does not confer a selective growth advantageon the cells.
Another phenomenon that has been suggested to be important in the establish-
ment of cell lines latently infected with EBV is the integration of a viral genome
into cellular DNA (39, 40). Although integration has been observed in certain BLs
and LCL, it remains unclearwhether integration is necessary for the establishmentHURLEY AND THORLEYLAWSON
￿
2073
of latency, or is a fortuitous consequence of long-term association of viral and cel-
lular DNA in a few cell lines.
The r or lymphotropic herpesviruses commonly assume circular forms during
latency (41-43). a herpesviruses such as HSV have also been reported to exist in
either a circular or an "endless" form in latently infected brain and ganglia of mice
and humans (44, 45). Assumption of the circular form may then be common to
the latent state of all herpesviruses. At present, EBV provides the most accessible
model for the elucidation ofgeneralized mechanisms for the establishment and main-
tenance of latency by herpesviruses.
Summary
Linear EBV genomes undergo a transition to the circular form characteristic of
latency by 16-20 h post-infection. This transition requires that the infected cells be
activated to the Gi stage of the cell cycle. Cellular proliferation and expression of
the activation marker CD23 were not required. Nevertheless, 36 h post-infection,
only cells expressing CD23 contained covalently closed, circular episomes (CCC),
at an average of one copy per cell. Since the presence of CD23 at this time is predic-
tive that a cell will immortalize, we suggest that the presence of CCC is required
for CD23 expression and subsequent immortalization. The one CCC present in each
CD23 + cell did not undergo amplification until well after the cells had acquired
all of the characteristic phenotypic markers of immortalization. Therefore, while
amplification is not necessary for proliferation and immortalization, circularization
of a single genome is crucial to the establishment and maintenance oflatency by EBV.
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